HIGHLIGHTS
- who: Neehar D. Parikh from the United States United States have published the Article: Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study, in the Journal: (JOURNAL)
- what: The authors aimed to determine patient preferences and trade-offs for second-line treatment in patients with HCC. The authors aimed to characterize patient preferences when patients are given the option between a profile similar to an oral tyrosine kinase inhibitor (regorafenib) versus a profile similar to an infusional therapy (ramucirumab), with . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.